ArticleIranian journal of pharmaceutical research : IJPR
Protective Effect of Methoxsalen on Spinal Cord Injury in the Rat Model via Regulation of the PI3K/Akt Pathway.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal cord injury (SCI) is a major cause of disability, and the management of secondary injury remains challenging. Objectives: This study evaluated the protective effects of methoxsalen against SCI and investigated its potential mechanism of action. Methods: Network pharmacology and molecular docking were performed to identify the molecular targets of methoxsalen for the treatment of SCI. SCI was induced in rats by laminectomy, and methoxsalen (12 and 24 mg/kg, p.o.) was administered for 14 days after SCI induction. Motor function was assessed using the Basso, Beattie, and Bresnahan (BBB) score, and spinal cord inflammation was evaluated by assessing water deposition and inflammatory cytokine levels in SCI rats. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to assess the mRNA expression of phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) in SCI rats. Results: Molecular docking data showed that methoxsalen interacted with AKT, PI3K, and nuclear factor-κB (NF-κB), with binding energies of -9.1, -9.2, and -9.4 kcal/mol, respectively. The BBB score was significantly improved in the methoxsalen-treated group compared with the SCI group. MDA (18.6 ± 0.9 nmol/mg) and ROS (1.30 ± 0.04-fold) levels were significantly reduced, whereas GSH (92.0 ± 2.2 µM/mg) and SOD (54.2 ± 1.3 U/mg) levels were increased in the methoxsalen-treated group compared with the SCI group. Methoxsalen treatment ameliorated inflammatory alterations and cytokine levels in rats with SCI. The mRNA expression of PI3K, AKT, and NF-κB was attenuated in spinal cord tissue from methoxsalen-treated rats with SCI. Conclusions: Methoxsalen treatment improved motor function in rats with SCI by modulating the PI3K/AKT signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.